A group of multinational pharmaceutical companies reported results in the third quarter surfaced, quickly come to watch!

"Pharmaceutical network industry dynamics" with the domestic listed companies in the third quarter of the report has been disclosed, multinational pharmaceutical companies in the third quarter of the situation also surfaced.
From the public information point of view, so far, Abbott Pharmaceuticals, Johnson and Johnson, Roche and other multinational pharmaceutical companies have issued three-quarter earnings forecast, many of them said the second quarter after the performance of different degrees of recovery.
third-quarter results from Abbott Pharmaceuticals showed revenue of $8.853 billion, up 9.6 percent from a year earlier, exceeding expectations of $8.53 billion.
in terms of business segments, medical device revenue was $3.170 billion, up 3.4% YoY, diagnostic revenue was $2.640 billion, up 38.2% YoY, nutrition revenue was $1.924 billion, up 2.6% YoY, and drug revenue was $1.099 billion, down 9.3% YoY.
net profit for the quarter was $1,232 million, up 28.5 percent from a year earlier.
, Abbott Pharmaceuticals is a global healthcare company with a wide range of products in the fields of nutrition, pharmaceuticals, medical devices, diagnostic instruments and reagents.
companies in more than 130 countries and regions around the world.
's third-quarter 2020 report showed total revenue for the first three quarters was $60,109 million, down 2% year-on-year due to the outbreak, while adjusted net profit was $16.468 billion, down 9.9% year-on-year and with a net profit margin of 27%.
2020Q3 revenue of $21,082 million, up 1.7% YoY, and adjusted net profit of $5.868 billion, up 3.5% YoY.
is a medical and health care products and consumer care products company, its business mainly includes the three major sectors of daily (health consumption), medical devices and pharmaceuticals; $500 million, $16.37 billion (-15%), $33.304 billion (-5.2%), with revenues of 17%, 27% and 55%, respectively.
drug sector grew significantly, with Darzalex, Imbruvica and the prostate cancer treatment Erleada growing at double-digit rates.
In addition, the sub-sectors of medical devices also recovered to varying degrees after the second quarter;
the first three quarters of this category fell by only 3.1%, Q3 single-quarter growth rate reached 13%, performance growth is mainly driven by atrial fibrillation-related surgery recovery.
third-quarter results from Roche Pharmaceuticals, the Pharmaceuticals giant, showed revenue of SFr14,698m in the third quarter of 2020, up 1 per cent year-on-year and below market expectations of SFr15.4bn.
revenue for the first three quarters of the year was SFr43.9bn, up 1 per cent year-on-year at constant exchange rates and 5 per cent year-on-year when the continued appreciation of the Swiss franc is included.
It is understood that although the first three quarters of related testing tools and new drugs revenue showed growth, but in the third quarter of Roche's global drug sales of the top four drugs, anti-tumor drugs quentin, avetin and lyxi monoantigen continued the previous trend, Q3 revenue decreased by 38%, 30% and 33% year-on-year.
also makes a series of new drug sales growth completely unable to offset the negative revenue of traditional drugs.
, Roche is a global leader in pharmaceuticals and diagnostics, offering innovative products and services from early detection, prevention, diagnosis and treatment to improve human health and quality of life.
more than 100 years of development, Roche Group's business has been in more than 100 countries around the world.